Stay updated on the most recent developments in Symeres.
High-throughput screening is a powerful tool to start drug-discovery programs. The success of this activity is highly dependent on the quality of the library that is screened. With this in mind, Symeres created the SymeGold library, which features compounds with a high degree of three-dimensionality.
At Symeres, we’re always looking to support our clients with novel and innovative ideas. Dr. André de Vries joined our ranks as of January 1, 2022.
In 2016, Stefan Krauss and Jo Waaler (University Hospital of Oslo, Norway) approached Symeres to optimize […]
Richard Baauw joined Symeres in 2017, along with his company Chiralix. Chiralix focused on the synthesis of optically active compounds.
This week, the 2021 Chemical & Engineering News list of ‘10 Start-Ups to Watch’ came out. […]
Symeres has quite a legacy when it comes to university collaborations. For many years, we’ve been […]
While working in big pharma, Dr. Chris Teleha spent years working with CROs in the development […]
COVID-19 has changed how we interact with people and has forced us to re-evaluate how we […]
The timely availability of high-quality APIs accelerates further investigation by our clients. To meet these pressing API needs, Symeres enables a route-scouting investigation for the API of interest.